• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    iSpecimen Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    11/7/25 4:30:31 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ISPC alert in real time by email
    false 0001558569 0001558569 2025-11-07 2025-11-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)
    OF THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): November 7, 2025

     

    iSpecimen Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-40501   27-0480143
    (State or other jurisdiction
    of Incorporation)
      (Commission File Number)   (IRS Employer
    Identification No.)

     

    8 Cabot Road, Suite 1800
    Woburn, MA 01801

    (Address of principal executive offices, including zip code)

     

    Registrant’s telephone number, including area code: (781) 301-6700

     

    Not Applicable

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   ISPC   The Nasdaq Stock Market LLC

     

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On November 7, 2025, the Board of Directors (the “Board”) of iSpecimen Inc. (the “Company”) appointed Ms. Katharyn Field to serve as Chief Executive Officer, Secretary, and Treasurer of the Company, effective immediately. Ms. Field will continue to serve as President of the Company. On the same date, Mr. Robert Bradley Lim stepped down as Chief Executive Officer, Secretary, and Treasurer of the Company and resigned as a member of the Board, effective immediately.

     

    Ms. Field, 41, has served as President since February 2025 and was previously a director from September 2024 until her appointment as President. Ms. Field has a background which includes positions spanning both the private and public sectors and brings a wealth of experience and expertise in strategy consulting and executive leadership. Ms. Field is currently the chief executive officer and Chairman of Halo Collective Inc., a cannabis company, where she has served since May 2019, an Executive Director at Akanda Corporation (Nasdaq: AKAN), a medical cannabis company, where she has served since June 2022, and a director and Vice President of Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, where she has served as director since July 2024. Previously, she served as a director of Elegance Brands from March 2021 until March 2022. She has held prominent positions at renowned organizations such as The White House in the office of the public liaison, The Brookings Institution as a manager of operations, and Bain & Company as a consultant. In 2014, Ms. Field entered the cannabis industry and played a pivotal role in the procurement, build-out, and sale of one of the original vertically integrated licensed medical marijuana treatment centers in Florida. Subsequently, she operated a strategy consulting practice focused on cannabis and served as Executive Vice President of Corporate Development at MariMed from 2018 to 2019. Ms. Field holds an MBA in Economics from Columbia Business School and a BA in Public Policy with honors from Stanford University. Ms. Field is well-qualified to serve as Chief Executive Officer, President, Secretary, and Treasurer of the Company due to her experience and expertise in strategy consulting and executive leadership.

     

    There were no changes at this time to Ms. Field’s compensation or other terms of employment in connection with this appointment.

     

    In connection with Mr. Lim’s resignation, the Board appointed Mr. Arphing (Tommy) Lee as an independent director to fill the resulting vacancy, effective immediately. Mr. Lee was also appointed to serve on the Audit Committee and the Nominating and Corporate Governance Committee of the Board.

     

    Mr. Lee, 34, is a management consultant and professional engineer with extensive experience leading large-scale, multidisciplinary transformation initiatives across the technology, energy, and resources sectors. Since March 2025, Mr. Lee serves as Project Manager/Senior Technical Consultant – Management Operating Systems of Fuse Advisors, a Canadian boutique engineering consulting company, where he designs and implements integrated systems that define how large organizations plan, execute, and continuously improve their work. Mr. Lee has served as an advisor on the UBC Mining Industry Advisory Council (IAC) for the Norman B. Keevil Institute of Mining Engineering since May 2023. Previously, he served at Accenture, a leading global professional services company, as Mining & Natural Resources Manager from May 2024 to March 2025 and as Mining & Natural Resources Consultant from August 2022 to May 2024; AMC Consultants, a global mining consultancy firm, as Senior Mining Engineer from September 2021 to August 2022; ABH Engineering, a mining engineering company offering geology, mining, and processing services, as Senior Mining Engineer from March 2021 to September 2021; Baffinland Iron Mines, a Canadian mining company, as Short Range & Mid-Range Mine Planner from November 2018 to September 2021; and at organizations such as Imperial Oil and Barrick Gold in mining engineering roles. Mr. Lee holds a Bachelor of Applied Science, Mining and Mineral Processing Engineering from the University of British Columbia and holds the designation of registered professional engineer (P.Eng). Mr. Lee is well-qualified to serve on the Board due to his extensive engineering experience and background in corporate strategy, operational excellence, and the design and implementation of management systems that enable organizations to operate with precision and efficiency.

     

    There are no arrangements or understandings between Mr. Lee and any other person pursuant to which he was selected as a director. Mr. Lee has no family relationships with any director or executive officer of the Company, and there are no transactions in which Mr. Lee has an interest requiring disclosure under Item 404(a) of Regulation S-K.

     

    Mr. Lim has served as Chief Executive Officer, Secretary, Treasurer, and Director since December 2024. To the Company’s knowledge, his resignation did not involve a disagreement with the Company, its management, or the Board on any matter relating to the Company’s operations, policies, or practices within the meaning of Item 5.02(a) of Form 8-K. The Board expresses its appreciation for Mr. Lim’s contributions to the Company and wishes him success in his future endeavors.

     

    1 

     

     

    The Board and management team remain focused on executing the Company’s objectives and do not anticipate any disruption to the Company’s operations as a result of these leadership changes. As a result of these changes, the Audit Committee is now composed of Mr. Anthony Lau, Mr. Avtar Dhaliwal, Ms. Yuying Yang, and Mr. Lee, with Mr. Lau serving as Chair. The Compensation Committee remains composed of Mr. Lau, Ms. Yang, and Mr. Dhaliwal, with Ms. Yang serving as Chair. The Nominating and Corporate Governance Committee is now composed of Mr. Dhaliwal, Ms. Yang, Mr. Lau, and Mr. Lee, with Mr. Dhaliwal serving as Chair. The Board has determined that Mr. Dhaliwal, Mr. Lau, and Ms. Yang continue to qualify as independent directors. The Board is continuing to evaluate next steps with respect to broader management and director succession planning as well as committee composition and will make additional disclosures as appropriate.

     

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit No.   Description
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

    2 

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: November 7, 2025

     

    iSPECIMEN INC.  
         
    By: /s/ Katharyn Field  
      Name: Katharyn Field  
      Title: Chief Executive Officer        

     

     

    3 

     

    Get the next $ISPC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ISPC

    DatePrice TargetRatingAnalyst
    1/4/2022$20.00Buy
    Craig-Hallum
    11/22/2021$10.00 → $12.00Buy
    EF Hutton
    More analyst ratings

    $ISPC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Craig-Hallum initiated coverage on iSpecimen with a new price target

    Craig-Hallum initiated coverage of iSpecimen with a rating of Buy and set a new price target of $20.00

    1/4/22 7:34:53 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    EF Hutton reiterated coverage on iSpecimen with a new price target

    EF Hutton reiterated coverage of iSpecimen with a rating of Buy and set a new price target of $12.00 from $10.00 previously

    11/22/21 11:51:50 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    iSpecimen Approached by Crypto Currency Companies for $200 Million Treasury Discussions

    Woburn, Massachusetts--(Newsfile Corp. - September 4, 2025) - iSpecimen Inc. (NASDAQ:ISPC), (the "Company"), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced an update on its major strategic initiative aimed at integrating digital assets into its business model. The Company had previously announced that it is pursuing a strategic initiative aimed at integrating digital assets into its business model, by seeking to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem.Since announcing its intentions in August, iSpecimen has been approached by several Crypto currency-related compan

    9/4/25 4:05:00 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Announces Completion of Milestone 1 in Digital Transformation Journey with Salestack Platform

    Woburn, Massachusetts--(Newsfile Corp. - August 21, 2025) - iSpecimen Inc. (NASDAQ:ISPC), an online marketplace for human biospecimens, today announced the successful completion of Milestone 1 in its digital transformation program powered by Salestack Solutions. This critical achievement marks the installation of the Salestack platform and provisioning of modern infrastructure—laying the foundation for accelerated innovation, operational efficiency, and long-term scalability.Milestone 1 focused on enhancing the legacy iSpecimen Marketplace® infrastructure with Salestack's next-generation, cloud-native architecture, expected to deliver immediate value through:Infrastructure-as-Code (IaC): bui

    8/21/25 8:00:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen to Establish $200M Corporate Treasury Built Around Solana Cryptocurrency with BlockArrow

    Woburn, Massachusetts--(Newsfile Corp. - August 7, 2025) - iSpecimen Inc. (NASDAQ:ISPC), a technology-enabled company modernizing the way human biospecimens are sourced for scientific research, today announced a major strategic initiative aimed at integrating digital assets into its business model. The company is looking to build an up to $200 million corporate treasury reserve based on the Solana blockchain ecosystem.iSpecimen has retained WestPark Capital to advise on the initiative with any funds that may be allocated or raised to be earmarked for building a digital asset treasury that will support long-term value creation and fuel innovation across iSpecimen's digital infrastructure. To

    8/7/25 4:05:00 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Lee Arphing

    3 - iSpecimen Inc. (0001558569) (Issuer)

    11/19/25 2:02:39 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Liang Yuying

    3 - iSpecimen Inc. (0001558569) (Issuer)

    1/30/25 4:05:21 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 3 filed by new insider Lim Robert Bradley

    3 - iSpecimen Inc. (0001558569) (Issuer)

    12/13/24 6:30:47 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    SEC Filings

    View All

    iSpecimen Inc. filed SEC Form 8-K: Other Events

    8-K - iSpecimen Inc. (0001558569) (Filer)

    12/1/25 4:05:28 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - iSpecimen Inc. (0001558569) (Filer)

    11/21/25 5:20:34 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form DEF 14A filed by iSpecimen Inc.

    DEF 14A - iSpecimen Inc. (0001558569) (Filer)

    11/21/25 5:17:27 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Leadership Updates

    Live Leadership Updates

    View All

    iSpecimen Appoints Eric Langlois as Chief Revenue Officer

    LEXINGTON, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that it appointed Eric Langlois as Chief Revenue Officer, effective immediately. Mr. Langlois previously served as the Company's Senior Vice President of Sales and Business Development. In this new role, Mr. Langlois will manage a restructured commercial team aimed at executing on Company initiatives to better align customer needs, streamline collaboration, support innovation and productivity necessary for driving sca

    1/24/23 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Names Tracy Curley as Chief Executive Officer

    LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that its Board of Directors has appointed Tracy Curley, former Interim CEO, as CEO, effective immediately. "I am grateful to the Board and the entire team at iSpecimen for their support over the past four months, and for the confidence they have shown in my ability to lead the Company," said Tracy Curley, CEO of iSpecimen. "The progress we've made this year in terms of operational and financial execution is encouragi

    1/10/23 1:11:01 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Appoints Joseph J. Basile to Board of Directors

    LEXINGTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that the Company has appointed Joseph J. Basile to iSpecimen's Board of Directors (the "Board"), as well as the audit committee and the nominating and corporate governance committee of the Company, effective November 28, 2022. Mr. Basile is replacing Margaret H. Lawrence as an independent director. Mr. Basile is a sought-after strategic advisor, an accomplished business leader, a skilled negotiator, a trained mediato

    12/5/22 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Financials

    Live finance-specific insights

    View All

    iSpecimen Reports Second Quarter 2024 Results

    Revenue increased 76% year-over-year to approximately $2.86 million Brielan Smiechowski Named SVP of Sales and Business Development LEXINGTON, Mass., Aug. 06, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three and six month periods ended June 30, 2024. "iSpecimen's strong results reflect the progress we have made towards operational improvements throughout the Company this year, resulting in a 76% increase in revenue to $2.86 million for

    8/6/24 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen to Report Second Quarter 2024 Results on August 6, 2024

    LEXINGTON, Mass., July 25, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the second quarter ended June 30, 2024, before the market opens on Tuesday, August 6, 2024. The Company will host a conference call and audio webcast that morning at 8:30 a.m. Eastern Time featuring remarks by Tracy Curley, CEO. Event:iSpecimen Second Quarter 2024 Results Conference Call  Date:Tuesday, August 6, 2024  Time:8:30 a.m. Eastern Time  Live Call:+1-800-717-1738

    7/25/24 4:05:00 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    iSpecimen Reports First Quarter 2024 Results

    LEXINGTON, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ:ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists requiring biospecimens for medical research with a network of healthcare specimen providers, today reported its financial and operating results for the three-month period ended March 31, 2024. "iSpecimen made tremendous progress during the first quarter advancing our most promising operational initiative, Next Day Quotes, a program that expedites the biospecimen transaction process, which has helped elevate our market position and is expected to contribute meaningfully to our growth in 2024 and beyond," said Tracy Curley, C

    5/7/24 7:30:00 AM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ISPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by iSpecimen Inc. (Amendment)

    SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

    2/13/24 5:17:07 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13D filed by iSpecimen Inc.

    SC 13D - iSpecimen Inc. (0001558569) (Subject)

    4/17/23 1:27:18 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by iSpecimen Inc. (Amendment)

    SC 13G/A - iSpecimen Inc. (0001558569) (Subject)

    2/13/23 4:04:55 PM ET
    $ISPC
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care